These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1200814)

  • 1. Bladder training: its role in evaluating the effect of an antispasticity drug on voiding in patients with neurogenic bladder.
    Roussan MS; Abramson AS; Levine SA; Feibel A
    Arch Phys Med Rehabil; 1975 Nov; 56(11):463-8. PubMed ID: 1200814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological rebound: a tool in the evaluation of antispasticity drugs.
    Roussan MS; Abramson AS; Levine SA; Feibel A
    Arch Phys Med Rehabil; 1976 Nov; 57(11):504-7. PubMed ID: 791192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of the neurogenic detrusor-sphincter dyssynergy with lioresal].
    Haubensak K; Blümlein H
    Helv Chir Acta; 1978 Jul; 45(3):339-42. PubMed ID: 701072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new antispasticity drug on neurogenic bladder function: preliminary report.
    Roussan MS; Gordon S
    Arch Phys Med Rehabil; 1973 Jul; 54(7):296-301. PubMed ID: 4718236
    [No Abstract]   [Full Text] [Related]  

  • 6. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB; Babanina GA
    Urologiia; 2007; (3):15-9. PubMed ID: 17722614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurogenic bladder dysfunction in patients with neoplastic spinal cord compression: adaptation of the bladder management strategy to the underlying disease.
    Reitz A; Haferkamp A; Wagener N; Gerner HJ; Hohenfellner M
    NeuroRehabilitation; 2006; 21(1):65-9. PubMed ID: 16720939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of oxybutynin hydrochloride on neurogenic bladder].
    Toma H; Nakamura R
    Hinyokika Kiyo; 1986 Jun; 32(6):907-11. PubMed ID: 3532726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effect of Robaveron tablet (KN-7) on neurogenic bladder].
    Endo H; Sonoda T; Koyanagi T; Maru A; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1984 Jan; 30(1):135-44. PubMed ID: 6375318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of anticholinergics on bladder tonus and on the voiding function].
    Kelly LU; Wehnert J
    Z Urol Nephrol; 1979 Oct; 72(10):765-9. PubMed ID: 532394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urological management of female spinal cord injury patients--clinical survey of 28 cases].
    Momose H; Yamamoto M; Okamura K; Shiomi T; Yamada K
    Hinyokika Kiyo; 1987 Feb; 33(2):171-6. PubMed ID: 2884846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of capsaicin-sensitive afferent fibers in the lower urinary tract dysfunction induced by chronic spinal cord injury in rats.
    Cheng CL; de Groat WC
    Exp Neurol; 2004 Jun; 187(2):445-54. PubMed ID: 15144870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats.
    Khera M; Boone TB; Salas N; Jett MF; Somogyi GT
    BJU Int; 2007 Feb; 99(2):442-6. PubMed ID: 17313428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term urologic management of the patient with spinal cord injury.
    Perkash I
    Urol Clin North Am; 1993 Aug; 20(3):423-34. PubMed ID: 8351768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Memantine and neurogenic bladder disorders within the bounds of spastic conditions].
    Grossmann W; Schütz W
    Arzneimittelforschung; 1982; 32(10):1273-6. PubMed ID: 6891227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of percutaneous nephrolithotomy in patients with neurogenic bladder dysfunction.
    Rubenstein JN; Gonzalez CM; Blunt LW; Clemens JQ; Nadler RB
    Urology; 2004 Apr; 63(4):636-40. PubMed ID: 15072868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury.
    Merritt JL
    Arch Phys Med Rehabil; 1981 Nov; 62(11):558-61. PubMed ID: 7316711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative assessment of combined therapy of neurogenic hyperactivity of detrusor in patients with Parkinson's disease].
    Loran OB; Fedorova NV; Mazurenko DA; Khitarishvili EV
    Urologiia; 2006; (2):37-9, 41. PubMed ID: 16708587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.